Document resource
Background Empty pass, defined as a thrombectomy pass without clot retrieval, may reduce procedural efficiency and worsen first pass reperfusion. From the EXCELLENT 1000 registry, the incidence of empty passes were evaluated and independent predictors were identified.Methods The modified intention-to treat cohort (n=997) was analyzed. The primary outcome was empty pass without clots. Univariable and multivariable logistic regression were conducted to develop a predictive model. P-values <0.05 were considered significant and no multiplicity adjustment was applied. Variables with p < .05 in univariable regression were entered into the multivariable model, with additional clinically established risk factors prioritized for inclusion. Collinearity was assessed using a strict variance inflation factor cutoff of 2.Results At least one empty pass occurred in 119 of 997 patients (11.9%). In multivariable analysis, presence of a hyperdense artery sign on CT or susceptibility artery sign on MRI assessed by core lab was associated with lower odds of empty pass (OR 0.49, 95% CI 0.32 to 0.77, p=.006). Balloon guide catheter use was also associated with lower odds of empty pass (OR 0.64, 95% CI 0.41 to 0.99, p=.044). Longer time from groin puncture to last angiogram (in hours) was independently associated with higher odds of empty pass (OR 1.57, 95% CI 1.16 to 2.12, p=.003). Other variables including baseline characteristics, demographics, and comorbidities were screened but not statistically significant in the final model.Conclusion In this EXCELLENT 1000 patient analysis, radiographic thrombus signs and balloon guide catheter use were associated with lower odds of empty pass, while longer procedure duration was associated with higher odds. These findings may inform procedural planning and device strategy to reduce empty pass events.Disclosures B. Musmar: None. A. Siddiqui: 2; C; Consulting for Cerebrotech, Boston Scientific, Rapid Medical, Cordis, W.L. Gore, Peijia Medical, Corindus, StimMed, J&J, Viz-AI, Silk Road Medical, Piraeus, Medtronic, Penumbra, Hyperfine Operations,. T. Andersson: 2; C; Consultant for Anaconda, Cerenovus/Neuravi, Ceretrieve, Optimize Neurovascular, Rapid Medical and SPRYTE, and a founder and shareholder of Ceroflo. R. Nogueira: 2; C; Consultant for Anaconda Biomed, Astocyte, Biogen Inc, Brainomix, Cerebrotech, Cerenovus, Ceretrieve, Corindus Inc., Genentech, Hybernia, Imperative Care Inc, Medtronic USA Inc, NeuroVasc Technologies. D. Haussen: 2; C; Consulting for Vesalio, Cerenovus, Stryker, Brainomix, Poseydon Medical, Chiesi USA; data safety and monitoring board: Jacobs Institute; and stock options at VizAI. A. Yoo: 2; C; Dr Yoo reports receiving personal fees for serving as a consultant for Penumbra, Cerenovus, Philips, Vesalio, and the National Institute of Neurological Disorders and Stroke; nonfinancial support for. R. Hanel: 2; C; Dr. Hanel is a consultant for Medtronic, Balt, Stryker, Q’Apel Medical, Inc, Codman Neuro (J&J), Cerenovus, Microvention, Imperative Care, Inc, Phenox, Inc, Rapid Medical. O.O. Zaidat: 2; C; consulting for J&J; patent holder. W. Hacke: 2; C; consulting for J&J. T. Jovin: 2; C; Advisor and holds stock for Anaconda, Route 92, Viz.AI, FreeOx, Methinks, Galaxy, AptaTargets, Kandu, Gravity, Luminopia, Carlsmed, StataDx, Vastrax and Let’s Get Proof. He serves in an advisory capac. J. Fiehler: 2; C; Funding from the European Commission; personal consulting fees from Acandis, Cerenovus, Medtronic, Microvention, Phenox, Stryker, and Roche; consulting at Philips (no payments); payment or honoraria f. S. De Meyer: 6; C; travel support from J&J. D. Liebeskind: 6; C; Compensation from Genentech for consultant services; compensation from Medtronic for consultant services; compensation from Cerenovus for consultant services; compensation from Stryker for consultant. V. Inoa: 6; C; Grants or contracts from Medtronic, research funding to institution; consulting fees from Penumbra, Siemens, Microvention, Cerenovus, VizAI, Medtronic, Stryker, imperative care; payment or honoraria f. W. Humphries: 2; C; consulting for Cerenovus. K. Woodward: 2; C; Consultant for Penumbra. O. François: 2; C; Consultancy for iVascular, Cerenovus, GE Healthcare. E. Levy: 6; C; Shareholder/Ownership Interest: NeXtGen Biologics, RAPID Medical, Claret Medical, Cognition Medical, Imperative Care, Rebound Therapeutics, StimMed, Three Rivers Medical; Patent: Bone Scalpel; Honorar. H. Bozorgchami: None. S. Boor: None. J. Cohen: None. S. Dashti: 2; C; consulting for MicroVention, J&J, Cerenovus. . M. Taqi: 2; C; Consultant for Stryker, Rapid Medical, Balt USA, Medtronic. R. Budzik: 6; C; grants or contracts from Stryker, Cerenovus, and Microvention. C. Schirmer: 6; C; Compensation from Werfen USA LLC for other services; grants from Route 92 Medical Inc to other; compensation from Stryker Corporation for consultant services; compensation from Cerenovus for other ser. M. Hussain: 6; C; Compensation from Kaneka Pharma America LLC for consultant services; compensation from Stryker for data and safety monitoring services; compensation from Johnson & Johnson Health Care Systems Inc. for. R. De Leacy: 2; C; Consulting for J&J, Imperative Care, Stryker; ownership/investment interest in Vastrax, Q’Apel, Spartan Micro, Synchron, Endostream. A. Puri: 6; C; Dr Puri reports compensation from Merit Medical Systems Inc, Stryker, Route 92 Medical Inc, Johnson & Johnson Health Care Systems Inc, MicroVention Inc, Balt USA, LLC, Merit Medical Systems Inc, and M. R.V. Chitale: 6; C; Grants, consulting, and data safety monitoring for Medtronic; grants from J&J. C. Brekenfeld: None. J. Roy: None. S. Tjoumakaris: None. M. Gooch: None. R. Rosenwasser: None. P. Jabbour: 2; C; Consultant for Medtronic, MicroVention, Balt and Cerus Endovascular.